Knight Therapeutics, Inc. (GUD.TO)
10.83
+0.10
(+0.93%)
CAD |
TSX |
Oct 09, 16:00
Knight Therapeutics Enterprise Value : 988.44M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 988.44M |
| October 08, 2026 | 978.62M |
| October 07, 2026 | 976.65M |
| October 06, 2026 | 959.95M |
| October 05, 2026 | 942.27M |
| October 02, 2026 | 938.34M |
| October 01, 2026 | 969.78M |
| September 30, 2026 | 964.86M |
| September 29, 2026 | 941.29M |
| September 28, 2026 | 933.43M |
| September 25, 2026 | 935.40M |
| September 24, 2026 | 916.73M |
| September 23, 2026 | 915.75M |
| September 22, 2026 | 935.40M |
| September 21, 2026 | 924.59M |
| September 18, 2026 | 931.47M |
| September 17, 2026 | 929.50M |
| September 16, 2026 | 907.89M |
| September 15, 2026 | 902.98M |
| September 14, 2026 | 908.88M |
| September 11, 2026 | 892.18M |
| September 10, 2026 | 880.39M |
| September 09, 2026 | 897.09M |
| September 08, 2026 | 897.09M |
| September 04, 2026 | 907.89M |
| Date | Value |
|---|---|
| September 03, 2026 | 910.84M |
| September 02, 2026 | 874.50M |
| September 01, 2026 | 871.55M |
| August 31, 2026 | 873.52M |
| August 28, 2026 | 854.85M |
| August 27, 2026 | 866.64M |
| August 26, 2026 | 883.34M |
| August 25, 2026 | 882.36M |
| August 24, 2026 | 873.52M |
| August 21, 2026 | 873.52M |
| August 20, 2026 | 870.57M |
| August 19, 2026 | 889.23M |
| August 18, 2026 | 880.39M |
| August 17, 2026 | 885.30M |
| August 14, 2026 | 840.12M |
| August 13, 2026 | 829.32M |
| August 12, 2026 | 837.17M |
| August 11, 2026 | 857.80M |
| August 10, 2026 | 839.14M |
| August 07, 2026 | 883.34M |
| August 06, 2026 | 857.80M |
| August 05, 2026 | 834.23M |
| August 04, 2026 | 842.08M |
| July 31, 2026 | 891.20M |
| July 30, 2026 | 884.32M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 167.86M |
| Bausch Health Cos., Inc. | 31.48B |
| Cipher Pharmaceuticals, Inc. | 334.51M |
| BioSyent, Inc. | 188.68M |
| Revive Therapeutics Ltd. | 10.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.361M |
| Revenue (Quarterly) | 144.21M |
| Total Expenses (Quarterly) | 147.57M |
| EPS Diluted (Quarterly) | -0.0342 |
| Gross Profit Margin (Quarterly) | 38.94% |
| Profit Margin (Quarterly) | -2.33% |
| Earnings Yield | 1.39% |
| Operating Earnings Yield | 2.46% |
| Normalized Earnings Yield | 1.871 |